Minoxidil can cause hair growth as a side effect.
22 citations
,
June 2010 in “Experimental Dermatology” Lower MC2R expression may contribute to alopecia areata.
25 citations
,
November 2013 in “PLoS ONE” Estrogen and androgen signals control synaptic changes in rat brains.
61 citations
,
September 2011 in “Pain” PEA reduces pain by increasing neurosteroid synthesis in the spinal cord.
July 2025 in “American Journal on Addictions” Using 5-alpha reductase inhibitors may lower the risk of opioid addiction in men taking opioids.
September 2003 in “Reactions Weekly”
June 2026 in “Pharmaceuticals” 5α-Reductase inhibitors, like finasteride, can cause serious, persistent side effects not always listed in official drug information.
May 2024 in “Reactions weekly” 3 citations
,
December 2000 in “PubMed” CS-891 may effectively treat hair loss by blocking enzymes in hair follicles.
January 2025 in “Drug repurposing” New drug uses show promise but need more research.
Early NAS level changes affect alcohol consumption vulnerability.
January 2006 in “Zhongguo yaofang” The market for these drugs is expected to grow.
May 2026 in “Frontiers in Pharmacology” Long-term use of 5α-reductase inhibitors may improve survival in men with kidney cancer.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” Nanocarriers could improve minoxidil delivery for better hair loss treatment.
219 citations
,
January 2006 in “Drug Metabolism Reviews” DHEA affects multiple receptors and may help with metabolic issues, but its safety and effectiveness in humans are unclear.
43 citations
,
May 1978 in “JAMA” Minoxidil controls blood pressure but may cause kidney damage and needs diuretics to prevent swelling.
67 citations
,
August 2007 in “American Journal of Pathology” Overexpressing the mineralocorticoid receptor in mouse skin causes skin thinning, early skin barrier development, eye issues, and hair loss.
23 citations
,
January 2001 in “Chemical & Pharmaceutical Bulletin” New pregnane derivatives are effective at inhibiting an enzyme linked to hair loss and reducing oil gland activity.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.
35 citations
,
January 2018 in “Vitamins and hormones” DHEA affects various tissues by interacting with multiple receptors and can be converted into sex hormones.
52 citations
,
May 2011 in “Journal of Neuroendocrinology” PEA boosts allopregnanolone production and reduces oxidative stress in brain cells.
1 citations
,
October 2017 in “Food Additives & Contaminants: Part A” A new minoxidil-like substance, triaminodil, was found in an illegal hair growth supplement.
1 citations
,
September 2010 in “UEF eRepo (University of Eastern Finland)” Androgen receptors help prostate cancer cells grow and resist drugs.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
4 citations
,
July 2025 in “International Journal of Molecular Sciences” Targeting amphiregulin may improve treatment for fibrosis and cancer.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
3 citations
,
September 2025 in “ChemMedChem” Multitarget drugs are needed to better treat complex diseases.
18 citations
,
January 2002 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
16 citations
,
November 2018 in “Medicinal Chemistry” The compound GD-23 may reduce anxiety like diazepam by targeting the TSPO receptor.
April 2017 in “Actas urológicas españolas” 5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.